

High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients

Matti Vänskä,^{1*} Irma Koivula,^{2*} Sari Hämäläinen,² Kari Pulkki,³ Tapio Nousiainen,⁴ Esa Jantunen,^{4,5} and Auni Juutilainen^{1,5}

¹Department of Medicine, Kuopio University Hospital, Kuopio; ²Department of Medicine, Division of Infectious Diseases, Kuopio University Hospital, Kuopio; ³Department of Clinical Chemistry, University of Eastern Finland and Eastern Finland Laboratory Centre, Kuopio; ⁴Department of Medicine, Division of Hematology, Kuopio University Hospital, Kuopio; ⁵Institute of Clinical Medicine/Internal Medicine, University of Eastern Finland, Kuopio, Finland

*MV and IK contributed equally to this manuscript.

Citation: Vänskä M, Koivula I, Hämäläinen S, Pulkki K, Nousiainen T, Jantunen E, and Juutilainen A. High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients. *Haematologica* 2011;96(9):1385-1389. doi:10.3324/haematol.2011.044925

Online Supplementary Table S1. Association of the baseline characteristics with PTX3 on day 0 in 100 hematologic patients with febrile neutropenia after chemotherapy. The median of PTX3 on day 0 from the beginning of fever was 9.0 µg/L.

	PTX3 d0 below median (N=50)	PTX3 d0 above median (N=50)	P value
Male (n, % of all patients)	29 (58%)	32 (64%)	0.539
Age (years) (mean, range)	51 (18-70)	52 (22-66)	0.748
≥ 60 years (n, % of patients)	17 (34%)	15 (30%)	0.668
Duration of neutropenic fever (d) (mean, range)	4.5 (1-19)	6.3 (1-25)	0.174
Duration of neutropenia (d) (mean, range)	12.8 (4-30)	11.4 (3-80)	0.149
Comorbidities			
Cardiovascular disease	12 (24%)	7 (14%)	0.202
Diabetes	2 (4%)	4 (8%)	0.400
Other	12 (24%)	9 (18%)	0.461
Treatment			
BEAM	13 (26%)	19 (38%)	0.198
BEAC	4 (8%)	11 (22%)	0.050
HD-MEL	8 (16%)	13 (26%)	0.220
IAT	11 (22%)	3 (6%)	0.021
HD AraC-Ida	8 (16%)	0 (0%)	0.003
Id AraC-Ida	5 (10%)	4 (8%)	0.727
Mito-HD AraC	1 (2%)	0 (0%)	0.315

BEAM: carmustine, etoposide, cytarabine and melphalan; BEAC: carmustine, etoposide, cytarabine and cyclophosphamide; HD-MEL: high-dose melphalan; IAT: idarubicin, cytarabine, thioguanine; HD-AraC-Ida: high-dose cytarabine, idarubicin; Id AraC-Ida: intermediate dose cytarabine, idarubicin; Mito-HD AraC: mitoxantrone, high-dose cytarabine